Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242840 · ClinicalTrials.gov registry record · Phase 3
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
A Phase 3 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT00242840 is a Phase 3 study that has completed, run by ViiV Healthcare. The registered enrollment target is 20 participants.
The verdict
NCT00242840, a Phase 3 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will assess the efficacy of subsequent protease inhibitor (PI)-containing therapy in subjects who have acquired HIV-1 protease mutations whilst receiving a GW433908 (fosamprenavir)-containing regimen.
Interventions
- DRUG No intervention; Observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-06 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00242840
The ClinicalTrials.gov registry entry for NCT00242840 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention; Observational study is the first listed.
NCT00242840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00242840 about?
NCT00242840 is a clinical study titled "Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)". This study will assess the efficacy of subsequent protease inhibitor (PI)-containing therapy in subjects who have acquired HIV-1 protease mutations whilst receiving a GW433908 (fosamprenavir)-containing regimen.
What is the current status of trial NCT00242840?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2003-06. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00242840?
The interventions under investigation include: No intervention; Observational study (DRUG).
Who is sponsoring clinical trial NCT00242840?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.